There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...

ORLANDO, Fla. — Exagamglogene autotemcel (exa-cel, Casgevy), a CRISPR/Cas9 gene-editing therapy, showed efficacy in children aged 5-11 years with transfusion-dependent beta-thalassemia (TDT) or sickle ...

Shanling’s SCD3.3 treats SACD like it never died—true DSD output, a 212-resistor R2R DAC, tube stage, and enough engineering muscle to shame most “modern” players. Let’s be honest: outside the ...

Throughout medical school and into residency, Edward “Donnell” Ivy, MD, MPH, wanted to become a pediatrician, so he could help children avoid the suffering he’d experienced as a child with sickle cell ...

SCD seeks total returns with a primary focus on income, investing globally in companies with strong fundamentals and clear market advantages. The fund uses leverage to enhance returns, with interest ...

Imagine this: you’re in the middle of an important project, juggling deadlines, and collaborating with a team scattered across time zones. Suddenly, your computer crashes, and hours of work vanish in ...

ESC Heart Failure Late Breaker: Largest single LifeVest® WCD study of NICM and MI/CAD patients shows high appropriate treatment rates during early period of contemporary GDMT CHELMSFORD, ...

This article is part of a Health Affairs Forefront series on “The Future of Sickle Cell Disease Research and Care” with support from the American Society of Hematology. The articles in the series are ...

Robbie has been an avid gamer for well over 20 years. During that time, he's watched countless franchises rise and fall. He's a big RPG fan but dabbles in a little bit of everything. Writing about ...

A publicly funded consortium of University of California (UC) researchers and clinicians is one big step closer to realizing a decade-long plan to launch a CRISPR-based gene-editing trial for sickle ...